65 related articles for article (PubMed ID: 38531846)
41. Current and future therapeutic approaches for osteosarcoma.
Harrison DJ; Geller DS; Gill JD; Lewis VO; Gorlick R
Expert Rev Anticancer Ther; 2018 Jan; 18(1):39-50. PubMed ID: 29210294
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis.
Wang S; Juan J; Zhang Z; Du Y; Xu Y; Tong J; Cao B; Moran MF; Zeng Y; Mao X
Cell Death Dis; 2017 Sep; 8(9):e3058. PubMed ID: 28933784
[TBL] [Abstract][Full Text] [Related]
43. A balanced level of profilin-1 promotes stemness and tumor-initiating potential of breast cancer cells.
Jiang C; Ding Z; Joy M; Chakraborty S; Kim SH; Bottcher R; Condeelis J; Singh S; Roy P
Cell Cycle; 2017; 16(24):2366-2373. PubMed ID: 28699810
[TBL] [Abstract][Full Text] [Related]
44. Downregulated USP3 mRNA functions as a competitive endogenous RNA of SMAD4 by sponging miR-224 and promotes metastasis in colorectal cancer.
Wang Z; Yang J; Di J; Cui M; Xing J; Wu F; Wu W; Yang H; Zhang C; Yao Z; Zhang N; Jiang B; Su X
Sci Rep; 2017 Jun; 7(1):4281. PubMed ID: 28655924
[TBL] [Abstract][Full Text] [Related]
45. AKT/PKB Signaling: Navigating the Network.
Manning BD; Toker A
Cell; 2017 Apr; 169(3):381-405. PubMed ID: 28431241
[TBL] [Abstract][Full Text] [Related]
46. Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Wang X; Liu J
Biochem Pharmacol; 2016 Sep; 116():22-38. PubMed ID: 27381943
[TBL] [Abstract][Full Text] [Related]
47. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway.
Wang H; Sun N; Li X; Li K; Tian J; Li J
Oncol Rep; 2016 Jun; 35(6):3648-58. PubMed ID: 27035545
[TBL] [Abstract][Full Text] [Related]
48. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.
Youngblood VM; Kim LC; Edwards DN; Hwang Y; Santapuram PR; Stirdivant SM; Lu P; Ye F; Brantley-Sieders DM; Chen J
Cancer Res; 2016 Apr; 76(7):1825-36. PubMed ID: 26833123
[TBL] [Abstract][Full Text] [Related]
49. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J
Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526
[TBL] [Abstract][Full Text] [Related]
50. Molecular mechanisms of apoptosis and roles in cancer development and treatment.
Goldar S; Khaniani MS; Derakhshan SM; Baradaran B
Asian Pac J Cancer Prev; 2015; 16(6):2129-44. PubMed ID: 25824729
[TBL] [Abstract][Full Text] [Related]
51. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.
Wang S; Kollipara RK; Srivastava N; Li R; Ravindranathan P; Hernandez E; Freeman E; Humphries CG; Kapur P; Lotan Y; Fazli L; Gleave ME; Plymate SR; Raj GV; Hsieh JT; Kittler R
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4251-6. PubMed ID: 24591637
[TBL] [Abstract][Full Text] [Related]
52. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors.
Cui J; Song Y; Li Y; Zhu Q; Tan P; Qin Y; Wang HY; Wang RF
Cell Res; 2014 Apr; 24(4):400-16. PubMed ID: 24366338
[TBL] [Abstract][Full Text] [Related]
53. USP3 counteracts RNF168 via deubiquitinating H2A and γH2AX at lysine 13 and 15.
Sharma N; Zhu Q; Wani G; He J; Wang QE; Wani AA
Cell Cycle; 2014; 13(1):106-14. PubMed ID: 24196443
[TBL] [Abstract][Full Text] [Related]
54. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Burkhart RA; Peng Y; Norris ZA; Tholey RM; Talbott VA; Liang Q; Ai Y; Miller K; Lal S; Cozzitorto JA; Witkiewicz AK; Yeo CJ; Gehrmann M; Napper A; Winter JM; Sawicki JA; Zhuang Z; Brody JR
Mol Cancer Res; 2013 Aug; 11(8):901-11. PubMed ID: 23696131
[TBL] [Abstract][Full Text] [Related]
55. RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response.
Shiloh Y; Shema E; Moyal L; Oren M
FEBS Lett; 2011 Sep; 585(18):2795-802. PubMed ID: 21827756
[TBL] [Abstract][Full Text] [Related]
56. Cyclin D as a therapeutic target in cancer.
Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL
Nat Rev Cancer; 2011 Jul; 11(8):558-72. PubMed ID: 21734724
[TBL] [Abstract][Full Text] [Related]
57. Human USP3 is a chromatin modifier required for S phase progression and genome stability.
Nicassio F; Corrado N; Vissers JH; Areces LB; Bergink S; Marteijn JA; Geverts B; Houtsmuller AB; Vermeulen W; Di Fiore PP; Citterio E
Curr Biol; 2007 Nov; 17(22):1972-7. PubMed ID: 17980597
[TBL] [Abstract][Full Text] [Related]
58. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK
Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180
[TBL] [Abstract][Full Text] [Related]
59. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project.
Stiller CA; Bielack SS; Jundt G; Steliarova-Foucher E
Eur J Cancer; 2006 Sep; 42(13):2124-35. PubMed ID: 16919776
[TBL] [Abstract][Full Text] [Related]
60. Eph receptors and ephrins in neural development.
O'Leary DD; Wilkinson DG
Curr Opin Neurobiol; 1999 Feb; 9(1):65-73. PubMed ID: 10072375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
